For information only. Not investment advice, a recommendation, an offer or a solicitation, and without regard to any recipient’s objectives or circumstances. Figures come from third-party sources believed reliable but not guaranteed, and market data may be delayed. Past performance is not a reliable indicator of future results. | ||||||||||||||||||||||||||||||||||||||||||||||||||
![]() Novo NordiskNOVOB DC · Health Care · DKK Current priceDKK 271.45as of Nov 19, 2026 Summary
Analyst consensusBuy 5Hold 15Sell 5Strong Sell 124 analysts 3-year price (DKK)Factor profileMulti-factor score 11 / 100 Market data
Business descriptionNovo Nordisk A/S is a global healthcare company specializing in diabetes care, obesity, and other serious chronic diseases. Headquartered in Denmark, it is a pioneer in the development of GLP-1 receptor agonists and holds a dominant position in the global insulin and obesity markets. Competitive moatThe company benefits from immense intangible assets via patents on its GLP-1 therapies, specialized clinical data, and long-standing endocrinology relationships. Massive scale and manufacturing expertise in peptide production create high barriers to entry. Recent developments
Investment risks / red flags
Financials
Classification
|
Last updated: Aug 10, 2026
Current price: DKK 271.45 · Nov 19, 2026· DKK
CFRA Ratinghold
TBI Multi Score11
Theme Exposure
Loading graph…
Factor Profile (Spider Chart)
TBI ModelPrice Chart
NOVO-B.CO262.75DKK-16.4%
Daily closes · Yahoo Finance · TradingView does not carry this exchange
Business description
Novo Nordisk A/S is a global healthcare company specializing in diabetes care, obesity, and other serious chronic diseases. Headquartered in Denmark, it is a pioneer in the development of GLP-1 receptor agonists and holds a dominant position in the global insulin and obesity markets.
Competitive moat
The company benefits from immense intangible assets via patents on its GLP-1 therapies, specialized clinical data, and long-standing endocrinology relationships. Massive scale and manufacturing expertise in peptide production create high barriers to entry.
Recent developments
- 2026-08-05: Q2 2026 sales grew 3% CER (7% adjusted). Wegovy pill surpassed 5M cumulative U.S. prescriptions since its January launch, providing a strong commercial boost.
- 2026-07-31: Disappointing results from the ZEUS Phase 3 trial, where ziltivekimab (IL-6 inhibitor) failed to reduce major adverse cardiovascular events, increasing pipeline risk.
- 2026-07-15: Secured European Commission marketing authorization for the Wegovy pill (oral semaglutide 25mg) across all EU member states.
- Unprecedented demand for Wegovy leading to global supply constraints and significant capacity investments.
- Expanding clinical trials to prove cardiovascular and other secondary benefits of its GLP-1 drugs.
- Continuous R&D into next-generation oral and combination obesity therapies.
Investment risks / red flags
- ⚠️ Negative clinical trial updates (like the ZEUS failure) limit diversification outside of the core obesity/diabetes axis.
- Regulatory and political pressure regarding drug pricing and reimbursement.
- Intense competition from other pharmaceutical giants in the obesity space.
- Capacity constraints limiting near-term sales potential.
Market Data
Source: mkts.io · Nov 19, 2026, 00:00 UTC
Key Metrics
P/E (TTM)10.65
P/E (Fwd)12.03
Dividend4.25%
Beta0.37
52W HighDKK 409.95
52W LowDKK 224.25
Analyst Consensus
5
15
5
Buy5Hold15Sell5Strong Sell124 analysts
Consensus TargetDKK 299.91
+10.5% upside
Calendar Events
Next EarningsFeb 3, 2027
Ex-DividendAug 14, 2026
Financials
RevenueDKK 333.65B
Rev Growth5.60%
Earnings Growth-15.80%
Gross Margin83.33%
Op Margin50.78%
Profit Margin33.92%
EBITDADKK 181.56B
ROA19.05%
ROE58.38%
Rev/ShareDKK 75.25
Total CashDKK 46.35B
Total DebtDKK 134.48B
D/E Ratio61.74
Free Cash FlowDKK 32.75B
Op Cash FlowDKK 127.33B
Current Ratio0.84
Forward Estimates
| Period | EPS Est | Rev Est |
|---|---|---|
| 0q | 4.41 | DKK 79.58B |
| +1q | 6.37 | DKK 73.29B |
| 0y | 22.79 | DKK 310.52B |
| +1y | 22.57 | DKK 313.51B |
Earnings
Quarterly EPS
4Q2025
Est: 5.786.04Beat
1Q2026
Est: 5.416.63Beat
2Q2026
Est: 5.046.18Beat
3Q2026
Est: 4.895.79Beat
Annual
2022
Rev DKK 176.95BEarn DKK 55.52B
2023
Rev DKK 232.26BEarn DKK 83.68B
2024
Rev DKK 290.40BEarn DKK 100.99B
2025
Rev DKK 309.06BEarn DKK 102.43B
